Seizert Capital Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$37.9M |
| 2 |
Capital One
COF
|
+$17.6M |
| 3 |
Qualcomm
QCOM
|
+$14M |
| 4 |
Cigna
CI
|
+$13.5M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$9.49M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$46.7M |
| 2 |
Amgen
AMGN
|
+$40.4M |
| 3 |
Progress Software
PRGS
|
+$39.5M |
| 4 |
WCC
WESCO International
WCC
|
+$11.9M |
| 5 |
JPMorgan Chase
JPM
|
+$11.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.73% |
| 2 | Financials | 19.76% |
| 3 | Healthcare | 17.74% |
| 4 | Industrials | 13.62% |
| 5 | Consumer Discretionary | 9.68% |
Similar funds
Seizert Capital Partners's Q3 2025 Portfolio in Review
As of Q3 2025, Seizert Capital Partners held 187 positions worth $2.31B, up 1.5% from $2.28B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Seizert Capital Partners withdrew a net $80.2M in Q3 2025, closing 17 positions and reducing 81 holdings. Its most notable exit was Progress Software, an estimated $39.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Seizert Capital Partners opened a new position in Neurocrine Biosciences worth $9.83M.
- Seizert Capital Partners's largest Q3 2025 buy was Neurocrine Biosciences: 70,035 shares worth $9.83M.
- Seizert Capital Partners added most to Adobe in Q3 2025, an estimated $37.9M increase.
- Seizert Capital Partners's biggest Q3 2025 reduction was Bank of America, cutting an estimated $46.7M.
- Seizert Capital Partners fully exited Progress Software in Q3 2025, selling an estimated $39.5M.
- Seizert Capital Partners's ten largest holdings make up 30% of its $2.31B portfolio in Q3 2025.
- Seizert Capital Partners opened 15 new positions and closed 17 in Q3 2025.
- Seizert Capital Partners's portfolio value rose 1.5% quarter-over-quarter to $2.31B.
Based on Seizert Capital Partners's 13F filing for Q3 2025, filed 29 Oct 2025.